| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
FFN511 targets neuronal vesicular monoamine transporter 2 (VMAT2), a protein responsible for transporting monoamines including dopamine, serotonin, and norepinephrine into synaptic vesicles. By inhibiting serotonin binding to VMAT2 with IC50 = 1 µM, FFN511 serves as a fluorescent probe for studying monoamine transmission. It is taken up by VMAT2 into synaptic vesicles and released during exocytosis, allowing visualization of dopamine release.
|
|---|---|
| ln Vitro |
In cultivated mouse chromaffin cells, FFN511 (350 nM; 30 min) accumulates in a pattern comparable with LDCV, and the lipophilic base chloroquine eliminates this accumulation [1].
In vitro, FFN511 inhibits serotonin binding to VMAT2-containing membranes with IC50 = 1 µM. It is used as a fluorescent tracer to visualize dopamine release from individual presynaptic terminals using time-lapse microscopy. It can directly reflect release dynamics during exocytosis. These in vitro activities make FFN511 a valuable tool for studying synaptic transmission and monoamine release. |
| ln Vivo |
In vivo, FFN511 can be used to label dopaminergic nerve terminals in acute cortical striatal slices. It can directly reflect release dynamics during exocytosis. The compound is used as an optical tracer for studying dopamine release in living tissue. Specific in vivo efficacy data are limited as it is primarily a research tool for imaging applications.
|
| Enzyme Assay |
In vitro binding assays for FFN511 measure inhibition of serotonin binding to VMAT2-containing membranes. Membranes are incubated with radiolabeled serotonin and varying concentrations of FFN511. Bound radioactivity is measured, and IC50 = 1 µM is determined.
|
| Cell Assay |
Cell Viability Assay [1]
Cell Types: Mouse Chromaffin Cells Tested Concentrations: 350 nM Incubation Duration: 30 minutes Experimental Results: Accumulation in cultured mouse chromaffin cells (same as LDCV), and accumulation can be eliminated by the lipophilic base chloroquine , thereby collapsing the vesicle pH gradient. Cell-based assays for FFN511 are conducted in neuronal cultures or brain slices. Cells or tissues are incubated with FFN511, and its uptake into synaptic vesicles is visualized by fluorescence microscopy. Dopamine release is monitored by time-lapse microscopy following stimulation. |
| Animal Protocol |
In vivo animal experiments with FFN511 involve administration of the compound to animals, followed by imaging of brain slices or in vivo imaging. The compound is used to label dopaminergic terminals and study dopamine release dynamics. Specific protocols depend on the imaging system and research objectives.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of FFN511 have not been extensively characterized. The compound is a fluorescent dye used as a research tool. Storage: appropriately. Specific PK parameters such as half-life, Cmax, and bioavailability have not been reported.
|
| Toxicity/Toxicokinetics |
Safety and toxicology data for FFN511 are limited. The compound is for research use only and is not for human therapeutic use. Standard laboratory safety precautions should be followed when handling the compound. The compound should be stored properly and disposed of in accordance with applicable regulations.
|
| References | |
| Additional Infomation |
FFN511 has CAS number 1004548-96-2. It is a potent fluorescent false neurotransmitter that targets VMAT2 and inhibits serotonin binding with IC50 = 1 µM. It is used as an optical tracer for dopamine release. Purity: typically ≥95%. Not for human use; for research purposes only.
|
| Molecular Formula |
C17H20N2O2
|
|---|---|
| Molecular Weight |
284.352904319763
|
| Exact Mass |
284.152
|
| CAS # |
1004548-96-2
|
| PubChem CID |
23725121
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
538.5±50.0 °C at 760 mmHg
|
| Flash Point |
279.5±30.1 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.658
|
| LogP |
3.05
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
21
|
| Complexity |
462
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(C1=CC(=O)OC2=C3CCCN4CCCC(=C34)C=C12)CN
|
| InChi Key |
SKTIZSRPCXRDHX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H20N2O2/c18-6-5-11-10-15(20)21-17-13-4-2-8-19-7-1-3-12(16(13)19)9-14(11)17/h9-10H,1-8,18H2
|
| Chemical Name |
6-(2-aminoethyl)-3-oxa-13-azatetracyclo[7.7.1.02,7.013,17]heptadeca-1(17),2(7),5,8-tetraen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5168 mL | 17.5840 mL | 35.1679 mL | |
| 5 mM | 0.7034 mL | 3.5168 mL | 7.0336 mL | |
| 10 mM | 0.3517 mL | 1.7584 mL | 3.5168 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
